Caricamento azienda
Just reported
From Neurocrine Biosciences's results release of 2 novembre 2026; its quarterly report has since been filed.
Actual
1,12B USD
+41% y/y
+17% q/q
Guided
—
No guide given
Actual
1,96 USD
-3,9% y/y
+41% q/q
Guided
—
No guide given
Actual
331,3M USD
+39% y/y
+119% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Neurocrine Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited33,9B USDA
ELANElanco Animal Health Incorporated13,3B USDA
KNSAKiniksa Pharmaceuticals International, plc8,2B USDA+
LQDALiquidia Corporation5,2B USDA
BHCBausch Health Companies Inc.3,1B USDARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 ott 2026BAGraded B, now ACostruito dai documenti depositati da Neurocrine Biosciences, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Grade A+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 41 dello storico dei voti di Neurocrine Biosciences, Inc.. Gli altri 39 risalgono fino a novembre 2016.
